OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

Basit Öğe Kaydı
dc.contributor.authorBayan, Kadim
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorDal, Tuba
dc.contributor.authorAyaz, Celal
dc.contributor.authorTekin, Recep
dc.contributor.authorAkdemir, Irem
dc.contributor.authorSari, Tugba
dc.date.accessioned2024-04-24T17:18:23Z
dc.date.available2024-04-24T17:18:23Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV. Materials and method: A total of 57 adults with HCV infection who initiated treatment DAA were included in this study. Baseline, 4 weeks and 12 weeks data including clinical characteristics, laboratory results and adverse events (AEs) were recorded. Results: One patient left treatment at the second week. The majority of patients were female 33 (57.9 %) and HCV GT1b (80.7%). Of the patients, 43 (75.4 %) patients were treatment experienced with pegylated interferon +/- RBV and 14 (25.6%) patients were naive. Ten (17.5%) patients had liver cirrhosis, 3 patients renal insufficiency, 7 patients diabetes mellitus, and 6 patients hypertension. Mean baseline ALT and HCV RNA levels was 48.58 +/- 25.8 U/L and 2857661 +/- 7231938 IU/ml, respectively. At the end of the week 4, one patient had >15 IU/mL HCVRNA level, HCVRNA was negative in remaining patients and mean ALT levels was 34.7 +/- 17.01 U/L. Three (5.3%) patient had AEs. At the end of the week 12, HCVRNA was negative in all patients, mean ALT levels was 29.3 +/- 12.2 U/L, 8 (14%) patients had AEs. Conclusion: DAA was a safe and effective therapy with 100% SVR rate and low treatment discontinuation rate (1.7 %) in patients with HCV GT1, GT1a and GT1b. This was well tolerated and efficient treatment aproach in patients with liver cirrhosis, renal insufficiency, diabetes mellitus, and hypertension.en_US
dc.identifier.doi10.19193/0393-6384_2018_1_12
dc.identifier.endpage75en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85045700764
dc.identifier.scopusqualityN/A
dc.identifier.startpage71en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2018_1_12
dc.identifier.urihttps://hdl.handle.net/11468/18754
dc.identifier.volume34en_US
dc.identifier.wosWOS:000424878600012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectTreatmenten_US
dc.subjectGenotypeen_US
dc.titleOMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTSen_US
dc.titleOMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu